Media coverage about CymaBay Therapeutics (NASDAQ:CBAY) has been trending somewhat positive on Friday, according to Accern Sentiment. The research firm identifies negative and positive media coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. CymaBay Therapeutics earned a media sentiment score of 0.13 on Accern’s scale. Accern also gave news headlines about the biopharmaceutical company an impact score of 44.9940562759419 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.
Here are some of the news headlines that may have impacted Accern’s rankings:
- What Do You Say about Overbought stock: Cymabay Therapeutics, Inc. (CBAY) – Voice Of Analysts (analystsbuzz.com)
- Overbought Stock Recap: Cymabay Therapeutics, Inc. (CBAY) – Wall Street Morning (wallstreetmorning.com)
- Tandem Diabetes Care, Inc. (TNDM) is at $0.58 per share and Cymabay Therapeutics, Inc. (CBAY) is listed at $8.49 – Stocks Gallery (stocksgallery.com)
- Buy the position in Healthcare Stock: Cymabay Therapeutics, Inc. (CBAY) – Street Observer (press release) (streetobserver.com)
- CymaBay (CBAY) Announces Late-Breaking Presentation of Interim Results from Ongoing Phase 2 Study of Patients … – StreetInsider.com (streetinsider.com)
Several research firms have weighed in on CBAY. Piper Jaffray Companies reissued an “overweight” rating and issued a $12.00 target price on shares of CymaBay Therapeutics in a research note on Tuesday, July 25th. Cantor Fitzgerald reissued a “buy” rating and issued a $16.00 target price on shares of CymaBay Therapeutics in a research note on Tuesday, September 26th. Oppenheimer Holdings, Inc. increased their target price on CymaBay Therapeutics from $8.00 to $15.00 and gave the company an “outperform” rating in a research note on Thursday, July 20th. Citigroup Inc. reissued an “outperform” rating and issued a $15.00 target price (up previously from $8.00) on shares of CymaBay Therapeutics in a research note on Thursday, July 20th. Finally, Ifs Securities reissued a “strong-buy” rating on shares of CymaBay Therapeutics in a research note on Monday, July 17th. Two equities research analysts have rated the stock with a hold rating and ten have issued a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus target price of $14.00.
CymaBay Therapeutics (NASDAQ:CBAY) last announced its earnings results on Thursday, August 10th. The biopharmaceutical company reported ($0.31) EPS for the quarter, missing the consensus estimate of ($0.25) by ($0.06).
In other CymaBay Therapeutics news, SVP Charles Mcwherter bought 5,000 shares of the business’s stock in a transaction that occurred on Thursday, July 20th. The shares were bought at an average price of $7.43 per share, for a total transaction of $37,150.00. Following the transaction, the senior vice president now directly owns 5,100 shares in the company, valued at $37,893. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Sujal Shah bought 10,000 shares of the business’s stock in a transaction that occurred on Thursday, July 20th. The shares were acquired at an average price of $7.34 per share, for a total transaction of $73,400.00. Following the transaction, the insider now owns 75,891 shares in the company, valued at $557,039.94. The disclosure for this purchase can be found here. In the last 90 days, insiders have purchased 20,000 shares of company stock worth $144,750. 15.10% of the stock is owned by corporate insiders.
CymaBay Therapeutics Company Profile
CymaBay Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies to treat metabolic diseases, including serious rare and orphan diseases. The Company’s product candidates include Arhalofenate, MBX-8025 and MBX-2982. Arhalofenate is used to treat gout.
Receive News & Ratings for CymaBay Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CymaBay Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.